SEC Form 4 · accession 0001209191-16-095839
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Altshuler
Officer — EVP, Global Research and CSO
Period of report
Feb 2, 2016
Accepted (ET)
Feb 4, 2016 · 6:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 2, 2016 | A | 14,416 | $0.01 | A | 89,416 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $91.05 | Feb 2, 2016 | A | 28,735 | A | — | Feb 1, 2026 | Common Stock | 28,735 | 28,735 | D |
Explanation of responses
- F1Restricted stock unit award that vests in three equal installments on 2/10/2017, 2/10/2018 and 2/10/2019.
- F2The option vests in 16 quarterly installments from 02/02/2016.